Natera, Inc. is a diagnostic company that develops and commercializes molecular testing services worldwide.
There are two tests in their product portfolio, Panorama and Signatera.
Panorama is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses, including twin pregnancies.
Signatera is a ctDNA blood test used for molecular residual disease evaluation and surveillance of disease recurrence in previously diagnosed cancer patients.
The company focuses primarily on oncology, women's health and organ health.
Natera announced its first quarter figures on May 9.
GAAP loss per share was 56 cents on the dollar (better than analyst consensus expectations).
Its revenues are just over $368 million (up over 52% from the previous year).
Number of tests processed in the first quarter: 735,800 (over 17% increase compared to Q4 2023).
Oncology-focused tests: 114,800 (more than 61% increase from Q1 2023).
Gross margins improved significantly to 56.7% (compared to 38.7% a year ago).
Signatera accounted for the bulk of the company's testing volume.
Natera achieved cash flow breakeven in the 1st quarter, above expectations.
Natera's practices have led to a remarkable 150% rally in the stock since late October.
However, profitability on a GAAP basis is not expected to occur until 2026.
My comment: They are in the process of establishing the business, I think their growth is good, I am watching, but the company is very interesting to me.
The information, comments and recommendations contained herein are not within the scope of investment consultancy. Investment consultancy services are provided within the framework of the investment consultancy agreement to be signed between brokerage firms, portfolio management companies, banks that do not accept deposits and customers. The comments in this article are only my personal comments and these comments may not be appropriate for your financial situation and risk return. For this reason, investments should not be made based on the information and comments in my articles.
